Lv1
42 积分 2021-04-09 加入
有志者，事竟成！
Establishment and characterization of BMC-PDC-019: a novel patient-derived cell line of EGFR-mutant pulmonary adenocarcinoma transformed into small-cell lung cancer
1个月前
已完结
First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial
1个月前
已完结
Integrative single-cell RNA-seq and spatial transcriptomics analyses reveal diverse apoptosis-related gene expression profiles in EGFR-mutated lung cancer
1个月前
已完结
MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
1个月前
已完结
Can a High-Dose of Furmonertinib Effectively Address Unmet Needs in EGFR-Mutated NSCLC with Leptomeningeal Metastases?
1个月前
已完结
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC
4个月前
已完结
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC
4个月前
已完结
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
6个月前
已完结
The novel strategy to overcome the drug-resistant lung cancer: Dual targeting delivery of PROTAC to inhibit cancer-associated fibroblasts and lung cancer cells
6个月前
已完结
EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer
7个月前
已完结
皖公网安备34019202002308
